Latest From Biotech Now

The ‘Access to Medicines’ Debate: Throwing Patients Without Cures Under the Proverbial Bus

Access to Medicines

The vast majority of the world’s patients remain completely forgotten in the ‘access to medicines’ debate.   Many fail to understand how that elimination will affect the development of the cures and treatments of tomorrow, especially for rare diseases, cancers, and other serious unmet medical conditions. The Forgotten: 25 million Americans suffer from nearly 7000 rare diseases.  30 million European Union citizens suffer from between 6000 to 8000 rare diseases, 80% of which are of genetic origin Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

20th Anniversary of the BIO International Convention

Jim Greenwood

Next year BIO will celebrate the 20th anniversary of the BIO International Convention April 22-25 in Chicago. From a small beginning, our convention has grown into the most influential biotech meeting in the world, attracting more than 16,500 attendees from 65 countries and providing a wide array of education, exhibits and networking opportunities — including more than 25,000 partnering meetings expected during the 4-day event. As we look forward to the upcoming Convention, I cannot Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

World Diabetes Day: Get the Facts

logo

Today, November 14, is World Diabetes Day and advocacy organizations around the world are focused on raising awareness for prevention and treatment options. How prevalent is diabetes? According to the 2011 National Diabetes Fact Sheet, there are more than 25 million children and adults in the U.S. with diabetes, which includes more than 18 million people who have been diagnosed and an estimated seven million people who have not yet been diagnosed. Nearly 80 million Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

The Good, the Bad, and the Ugly for Biotech IPOs

2012-11-12-Technology-vs-HC-IPOs-btn

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They read about new biotechs debuting on the public market, but also hear bankers, VCs, and CEOs complaining about how the IPO window never really opened after 2008. The reality is that we are seeing positive developments and negative trends simultaneously. On the bright side, the cumulative number of IPOs is holding up. The recent pace of biotech IPOs mimics what Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Labeling Foes: Fight if You Want, But We’ve Got to Feed the World

Karen-Batra-Feature

There were still millions of votes left to be counted in California when advocates for biotech labeling admitted defeat, but vowed to rise from the ashes and take their fight to the national level. Twenty-four hours had barely gone by when the New York Times, LA Times, San Francisco Chronicle and Sacramento Bee – among others – were reporting that biotech opponents still wanted to fight. The Yes on 37 campaign accused our side of using “dirty money Read More >

Farmer Gene  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , , , , ,